Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Prelude Therapeutics Inc PRLD.OQ reported a quarterly adjusted loss of 42 cents​​ per share for the quarter ended March 31, identical to the same quarter last year. The mean expectation of three analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -47 cents to -46 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Prelude Therapeutics Inc's reported EPS for the quarter was a loss of 42 cents​.

• The company reported a quarterly loss of $32.09 million.

• Prelude Therapeutics Inc shares had risen by 7.0% this quarter and lost 35.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 5.6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.50

This summary was machine generated from LSEG data May 6 at 09:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)